Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes

被引:34
|
作者
De Blasio, Miles J. [1 ,2 ]
Huynh, Nguyen [1 ,3 ]
Deo, Minh [1 ]
Dubrana, Leslie E. [1 ]
Walsh, Jesse [1 ]
Willis, Andrew [1 ]
Prakoso, Darnel [1 ,2 ]
Kiriazis, Helen [4 ]
Donner, Daniel G. [4 ]
Chatham, John C. [5 ]
Ritchie, Rebecca H. [1 ,3 ,6 ,7 ]
机构
[1] Baker Heart & Diabet Inst, Heart Failure Pharmacol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sch BioSci, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia
[4] Baker Heart & Diabet Inst, Expt Cardiol, Melbourne, Vic, Australia
[5] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[6] Monash Univ, Dept Med, Melbourne, Vic, Australia
[7] Monash Univ, Cent Clin Sch, Dept Diabet, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
type; 1; diabetes; diabetic cardiomyopathy; cardiomyocyte hypertrophy; cardiac fibrosis; diastolic dysfunction; BETA-N-ACETYLGLUCOSAMINE; PROTEIN O-GLCNACYLATION; OXIDATIVE STRESS; CONTRACTILE DYSFUNCTION; HEXOSAMINE BIOSYNTHESIS; DIASTOLIC DYSFUNCTION; CARDIAC-HYPERTROPHY; SIGNALING PATHWAYS; HEART-FAILURE; UP-REGULATION;
D O I
10.3389/fphys.2020.00124
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The incidence of diabetes and its association with increased cardiovascular disease risk represents a major health issue worldwide. Diabetes-induced hyperglycemia is implicated as a central driver of responses in the diabetic heart such as cardiomyocyte hypertrophy, fibrosis, and oxidative stress, termed diabetic cardiomyopathy. The onset of these responses in the setting of diabetes has not been studied to date. This study aimed to determine the time course of development of diabetic cardiomyopathy in a model of type 1 diabetes (T1D) in vivo. Diabetes was induced in 6-week-old male FVB/N mice via streptozotocin (55 mg/kg i.p. for 5 days; controls received citrate vehicle). At 2, 4, 8, 12, and 16 weeks of untreated diabetes, left ventricular (LV) function was assessed by echocardiography before post-mortem quantification of markers of LV cardiomyocyte hypertrophy, collagen deposition, DNA fragmentation, and changes in components of the hexosamine biosynthesis pathway (HBP) were assessed. Blood glucose and HbA1c levels were elevated by 2 weeks of diabetes. LV and muscle (gastrocnemius) weights were reduced from 8 weeks, whereas liver and kidney weights were increased from 2 and 4 weeks of diabetes, respectively. LV diastolic function declined with diabetes progression, demonstrated by a reduction in E/A ratio from 4 weeks of diabetes, and an increase in peak A-wave amplitude, deceleration time, and isovolumic relaxation time (IVRT) from 4-8 weeks of diabetes. Systemic and local inflammation (TNF alpha, IL-1 beta, CD68) were increased with diabetes. The cardiomyocyte hypertrophic marker Nppa was increased from 8 weeks of diabetes while beta-myosin heavy chain was increased earlier, from 2 weeks of diabetes. LV fibrosis (picrosirius red; Ctgf and Tgf-beta gene expression) and DNA fragmentation (a marker of cardiomyocyte apoptosis) increased with diabetes progression. LV Nox2 and Cd36 expression were elevated after 16 weeks of diabetes. Markers of the LV HBP (Ogt, Oga, Gfat1/2 gene expression), and protein abundance of OGT and total O-GlcNAcylation, were increased by 16 weeks of diabetes. This is the first study to define the progression of cardiac markers contributing to the development of diabetic cardiomyopathy in a mouse model of T1D, confirming multiple pathways contribute to disease progression at various time points.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Progression of Type 1 diabetes in the spontaneously diabetic BB/S rat
    Bone, AJ
    Lally, F
    DIABETOLOGIA, 2002, 45 : A152 - A152
  • [42] EFFECTS OF VASOPRESSIN V2 RECEPTOR ANTAGONISM ON THE PROGRESSION OF DIABETIC NEPHROPATHY IN MOUSE MODEL OF TYPE 2 DIABETES
    ElBoustany, Ray
    Taveau, Christopher
    Chollet, Catherine
    Velho, Gilberto
    Bankir, Lise
    Roussel, Ronan
    Bouby, Nadine
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [43] Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes
    Saraheimo, Markku
    Forsblom, Carol
    Thorn, Lena
    Waden, Johan
    Rosengard-Barlund, Milla
    Heikkilae, Outi
    Hietala, Kustaa
    Gordin, Daniel
    Frystyk, Jan
    Flyvbjerg, Allan
    Groop, Per-Henrik
    DIABETES CARE, 2008, 31 (06) : 1165 - 1169
  • [44] The role of central obesity for progression of diabetic nephropathy in type 1 diabetes
    Parente, E.
    Mutter, S.
    Valo, E.
    Thorn, L.
    Forsblom, C.
    Harjutsalo, V.
    Groop, P. H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [45] Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes
    Fyhrquist, F.
    Tiitu, A.
    Saijonmaa, O.
    Forsblom, C.
    Groop, P. -H.
    JOURNAL OF INTERNAL MEDICINE, 2010, 267 (03) : 278 - 286
  • [46] Metabolite analysis in the type 1 diabetic mouse model
    Park, Sung Jean
    JOURNAL OF THE KOREAN MAGNETIC RESONANCE SOCIETY, 2021, 25 (03): : 33 - 38
  • [47] Diabetic nephropathy in a nonobese mouse model of Type 2 diabetes mellitus
    Mallipattu, Sandeep K.
    Gallagher, Emily J.
    LeRoith, Derek
    Liu, Ruijie
    Mehrotra, Anita
    Horne, Sylvia J.
    Chuang, Peter Y.
    Yang, Vincent W.
    He, John C.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2014, 306 (09) : F1008 - F1017
  • [48] The Role of Nox4 in Development of Diabetic Cardiomyopathy in Type 1 Diabetes
    Maalouf, Rita
    Eid, Assaad
    Gorin, Yves
    Escobar, Patricia
    Abboud, Hanna
    Bailey, Steven
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (11) : E201 - E201
  • [49] DIFFERENCES IN LONGTERM PROGRESSION IN DIABETIC NEUROPATHY BETWEEN TYPE 1 AND TYPE 2 DIABETES
    Kano, Hiroki
    Shibuya, Kazumoto
    Suichi, Tomoki
    Nakamura, Keigo
    Morooka, Marie
    Otani, Ryo
    Aotsuka, Yuya
    Misawa, Sonoko
    Kuwabara, Satoshi
    MUSCLE & NERVE, 2022, 66 : S77 - S77
  • [50] Impact of Soluble Schistosomal Egg Antigens on Type 1 Diabetes Mellitus in an Induced Diabetic Mouse Model
    Mohammed Y. Shakra
    Morsy R. M. Geneedy
    Haitham Kh. Ahmad
    Moamen A.I. Mazen
    Mostafa E. Mostafa
    Acta Parasitologica, 2025, 70 (3)